APROBATION OF PLATELET AGGREGATION INHIBITOR FROM ECHIS MULTISQUAMATIS SNAKE VENOM IN VITRO, IN VIVO AND EX VIVO

Snake venom-derived platelet aggregation inhibitors can be promising antiplatelet medications that can allow to avoid the risk of bleeding and treatment resistance, particularly in aspirin-resistant patients. Our study aimed to assess the effectiveness of a platelet aggregation inhibitor derived fro...

Full description

Saved in:
Bibliographic Details
Published inBiotechnologia acta Vol. 16; no. 5; pp. 55 - 60
Main Author Zhelavskyi, M.A
Format Journal Article
LanguageEnglish
Published National Academy of Sciences of Ukraine, Palladin Institute of Biochemistry 31.10.2023
Subjects
animal model
blood coagulation
blood plasma
disintegrin
platelet aggregation
platelets
thrombosis
Online AccessGet full text

Cover

More Information
Summary:Snake venom-derived platelet aggregation inhibitors can be promising antiplatelet medications that can allow to avoid the risk of bleeding and treatment resistance, particularly in aspirin-resistant patients. Our study aimed to assess the effectiveness of a platelet aggregation inhibitor derived from Echis multisquamatis snake venom in various settings, including in vitro, in vivo, and ex vivo. Methods. We examined a polypeptide from Echis multisquamatis venom, purified using a recently developed chromatography protocol, across multiple models. This polypeptide was introduced into platelet-rich blood plasma and administered intravenously to rats. The effects on platelet aggregation were assessed using aggregometry, focusing on ADP-induced aggregation. Results & Discussion. Our findings revealed that a concentration of 0.040 mg/ml significantly reduced platelet aggregation in vitro. Remarkably, this dosage also proved effective when administered intravenously in laboratory animals, reaffirming its potential as a robust antiplatelet agent. In the final phase of our study, the polypeptide demonstrated its ability to inhibit platelet aggregation in blood plasma of pregnant woman with aspirin resistance, presenting a promising avenue for innovative treatment approaches in such cases. Conclusion. This study underscores the potential of the Echis multisquamatis venom-derived polypeptide as a promising antiplatelet agent, effective in diverse scenarios, including aspirin resistance. Further research and clinical trials are imperative to fully harness its therapeutic potential.
ISSN:2410-7751
2410-776X
DOI:10.15407/biotech16.05.055